pirfenidone has been researched along with Scleroderma, Localized in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azuma, A; Fujita, K; Hayashihara, K; Miura, Y; Nei, T; Rin, S; Saito, T; Sekine, A; Takoi, H; Tanaka, T; Tsunoda, Y; Yatagai, Y | 1 |
| Guevara-Gutiérrez, E; Rodríguez-Castellanos, M; Sánchez-Enríquez, S; Tlacuilo-Parra, A; Vélez-Gómez, E | 1 |
1 trial(s) available for pirfenidone and Scleroderma, Localized
| Article | Year |
|---|---|
Pirfenidone gel in patients with localized scleroderma: a phase II study.
Topics: Administration, Topical; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Female; Gels; Humans; Male; Middle Aged; Pyridones; Scleroderma, Localized | 2015 |
1 other study(ies) available for pirfenidone and Scleroderma, Localized
| Article | Year |
|---|---|
Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease.
Topics: Aged; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Pyridones; Recovery of Function; Retrospective Studies; Scleroderma, Diffuse; Scleroderma, Localized; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vital Capacity | 2014 |